VTYX — Ventyx Biosciences Share News
0.000.00%
Last trade - 00:00Brief: Ventyx Biosciences Q1 Operating Expenses USD 41.768 Million
U.S. STOCKS ON THE MOVE-Viatris, National Fuel Gas, Moderna
Brief: Ventyx Biosciences Reports Clinical Data For Its Nlrp3 Inhibitor Portfolio And Provides Pipeline Updates At Virtual Investor Event
U.S. RESEARCH ROUNDUP-Duolingo, Mid-America Apartment Communities, Nextracker
Brief: Ventyx Biosciences Announces $100 Mln Private Placement Of Common Stock
Brief: Ventyx Biosciences Q4 Operating Expenses USD 50.346 Million
Brief: Ventyx Biosciences Inc Implements A 20% Reduction In WorkForce
Brief: Ventyx Biosciences Q3 Operating Expenses USD 57.951 Million
U.S. STOCKS ON THE MOVE-Vivid Seats, DocGo, Waters Corp
U.S. STOCKS ON THE MOVE-Zimmer Biomet, Olaplex, Datadog
Ventyx Biosciences hits record low on halting trials for psoriasis drug
U.S. STOCKS ON THE MOVE-Uber, Olaplex, Planet Fitness
Ventyx Biosciences plummets on halting trials for psoriasis drug
Brief: Ventyx Biosciences Announces Results From The Phase 2 Trial Of VTX958 In Patients With Moderate To Severe Plaque Psoriasis
Ventyx Biosciences Inc expected to post a loss of 92 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Hyatt Hotels, Walmart, Maxeon
U.S. STOCKS ON THE MOVE-Olema Pharma, Akamai Technologies, US banks
Ventyx falls as brokerages cut PT on underwhelming trial results
Brief: Ventyx Biosciences Announces Positive Results From The Phase 2 Trial Of Vtx002 In Patients With Moderate-To-Severely Active Ulcerative Colitis